|
|
Creator | Title | Description | Subject | Date |
1 |
|
Blumenthal, Donald K. | CYP2C9 catalytic domain showing positions of *2 and *3 polymorphisms | X-ray crystal structure of human CYP2C9 (PDB id=1R9O (http://www.rcsb.org/pdb/cgi/explore.cgi?pdbId=1R9O)) showing the positions of the amino acids altered by the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) polymorphisms relative to the six substrate recognition sites (SRSs). The Arg144 and Ile359... | Warfarin; CYP2C9*2; CYP2C9*3; P450 | 2006-08-30 |
2 |
|
Blumenthal, Donald K. | Ranolazine: a new antianginal agent with a novel mechanism of action | This animation (with audio) illustrates the mechanism of action of ranolazine (RANEXA), a novel antianginal drug that inhibits the late sodium current (late I Na) in cardiac myocytes. The animation first describes how the late sodium current can contribute to symptoms of myocardial ischemia by causi... | Angina; Myocardial Ischemia, Acute Coronary Syndrome; Voltage-Gated Sodium Channel, Late Sodium Current; Sodium-Calcium Exchanger; Calcium Overload; Ranolazine | 2006-09-19 |
3 |
|
Blumenthal, Donald K. | Structure of vardenafil in the active site of PDE5 | PyMol file (725 KB): http://ir.utah.edu/blumenthal/PyMol/PDE5_Vardenafil.pse Download PyMol software to view this file. Available for free educational use: http://pymol.sourceforge.net Quicktime Movie--High Resolution (4 MB): http://stream.lib.utah.edu/index.php?c=details&id=9288 Quicktime Movie--... | Levitra; Phosphodiesterase inhibitors; PDE; Enzymes; Intracellular cyclic nucleotide-mediated signaling; 110634 | 2006-07-14 |